OncoMatch/Clinical Trials/NCT06209606
Pilot Study Using Changes in Serum BCMA to Determine Disease Progression in Multiple Myeloma
Is NCT06209606 recruiting? Yes, currently enrolling (May 2026). This Early Phase 1 trial studies multiple treatments including Ruxolitinib Oral Tablet [Jakafi] and Lenalidomide for multiple myeloma.
Treatment: Ruxolitinib Oral Tablet [Jakafi] · Lenalidomide · Methylprednisolone — This is a phase 1, multicenter, open-label study evaluating the safety and efficacy of ruxolitinib, steroids and lenalidomide among MM patients who currently show progressive disease using BCMA to test progression.
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: lenalidomide (lenalidomide)
has received at least 2 prior regimens including lenalidomide, a proteasome inhibitor, and an anti-CD38 antibody
Must have received: proteasome inhibitor
has received at least 2 prior regimens including lenalidomide, a proteasome inhibitor, and an anti-CD38 antibody
Must have received: anti-CD38 antibody
has received at least 2 prior regimens including lenalidomide, a proteasome inhibitor, and an anti-CD38 antibody
Cannot have received: JAK inhibitor (ruxolitinib)
JAK inhibitor including ruxolitinib
Cannot have received: chemotherapy
Chemotherapy within 3 weeks of study drugs
Cannot have received: corticosteroid
Exception: ≤20 mg/daily prednisone or equivalent allowed
Corticosteroids (>20 mg/daily prednisone or equivalent) within 3 weeks of study drugs
Cannot have received: immunotherapy
Immunotherapy, antibody therapy, immunomodulatory drugs, or proteasome inhibitors within 3 weeks of study drugs
Cannot have received: antibody therapy
Immunotherapy, antibody therapy, immunomodulatory drugs, or proteasome inhibitors within 3 weeks of study drugs
Cannot have received: immunomodulatory drug
Immunotherapy, antibody therapy, immunomodulatory drugs, or proteasome inhibitors within 3 weeks of study drugs
Cannot have received: proteasome inhibitor
Immunotherapy, antibody therapy, immunomodulatory drugs, or proteasome inhibitors within 3 weeks of study drugs
Cannot have received: extensive radiation therapy
Exception: localized radiation therapy allowed
Extensive radiation therapy within 28 days before study drugs. Receipt of localized radiation therapy does not preclude enrollment.
Cannot have received: experimental drug or therapy
Use of any other experimental drug or therapy within 28 days of study drugs
Lab requirements
Blood counts
Absolute neutrophil count ≥ 1.5 x 10^9/L (≥ 1.0 x 10^9/L if BM ≥ 70% plasma cells); Platelet count ≥ 75 x 10^9/L (≥ 50 x 10^9/L if BM ≥ 70% plasma cells; if CrCl < 60 mL/min, platelets > 150 x 10^9/L); Hemoglobin ≥ 8.0 g/dL
Kidney function
Calculated or measured CrCl > 60 mL/minute per Cockcroft-Gault
Liver function
Total bilirubin levels ≤ 2.0 mg/dL; AST (SGOT) and ALT (SGPT) ≤ 2 x ULN
Cardiac function
No impaired cardiac function or clinically significant cardiac diseases, including: MI within 6 months, NYHA Class II+ heart failure, uncontrolled angina, significant pericardial disease, severe uncontrolled ventricular arrhythmias, LVEF below institutional normal, ECG evidence of acute ischemia or active conduction system abnormalities
Laboratory test results within these ranges at Screening and confirmed at enrollment prior to drug dosing on Cycle 1, Day 1: Absolute neutrophil count ≥ 1.5 x 10^9/L... Platelet count ≥ 75 x 10^9/L... Hemoglobin ≥ 8.0 g/dL... Calculated or measured CrCl > 60 mL/minute... Total bilirubin levels ≤ 2.0 mg/dL... AST (SGOT) and ALT (SGPT) ≤ 2 x ULN... Serum potassium 3.0 - 5.5 mEq/L
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Berenson Cancer Center · West Hollywood, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify